



PATENT Docket No. 252312005704

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 332777718 US

Date of Deposit: January 5, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. TECH CENTER 1600/2900

Shannon Thomas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Stephen M. COUTTS et al.

Serial No.: 09/752,533

Filing Date: December 29, 2000

For: CONJUGATES OF CHEMICALLY

DEFINED NON-POLYMERIC

VALENCY PLATFORM MOLECULES

AND BIOLOGICALLY ACTIVE MOLECULES (AS AMENDED)

Examiner: D. Lukton

Group Art Unit: 1653

SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

01/07/2004 CCHAU1 00000088 031952 09752533

02 FC:1806

180.00 DA

	This Su	pplemental Information Disclosure Statement is submitted:
	With	the application; accordingly, no fee or separate requirements are required.
	Befor	e the mailing of a first Office Action after the filing of a Request for Continued
	Exam	ination under § 1.114.
	Withi	n three months of the application filing date or before mailing of a first Office
	Actio	n on the merits; accordingly, no fee or separate requirements are required.
\boxtimes	After	receipt of a first Office Action on the merits but before mailing of a final Office
	Actio	n or Notice of Allowance.
		A fee is required. A check in the amount of is enclosed.
	\boxtimes	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee
	•	is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmitta
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 252312005704. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated:

January 5, 2004

Respectfully submitted,

By:

Shannon Thomas

Registration No. 52,285

Morrison & Foerster LLP 755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (650) 813-5744 Facsimile: (650) 494-0792

3

AAIL BATE SANCELLED

JAN 0 5 2084

PTO/SB/08 (2-92) Sheet 1 of 4

Form P 1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docker 3 amber 252312005704

Application Number 09/752,533

Stephen M. COUTTS et al.

Filing Date December 29, 2000

Group Art Unit 1653

Mailing Date January 5, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	07/12/2001	2001/0007765	Harris et al.			
	2.	06/27/2002	2002/0082400	Coutts et al.			
	3.	01/23/2003	2003/0018190	Jones			
	4.	08/28/2003	2003/0162953	Coutts et al.			
	5.	01/13/1981	4,245,110	Engelhard et al.			
	6.	01/22/1991	4,987,130	Tsushima et al.			
	7.	12/28/1993	5,274,123	Deruelle et al.			v.
	8.	09/02/1997	5,663,395	Göbel et al.			
	9.	09/30/1997	5,672,662	Harris et al.			
	10.	10/07/1997	5,674,911	Emanuele et al.			
	11.	11/25/1997	5,691,387	Emanuele et al.			
	12.	12/16/1997	5,698,664	Allcock et al.			
	13.	12/01/1998	5,844,056	Kennedy et al.		_	
	14.	08/03/1999	5,932,462	Harris et al.			
	15.	11/23/1999	5,990,237	Bentley et al.			
	16.	04/09/2002	6,368,612	Lanza et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Transl YES	ation NO
	17.	10/09/1975	DE 24 12 217	Germany			Abstract	
	18.	08/17/1988	EP 0 278 621	Europe				
	19.	04/02/1998	PT 96503	Portugal			Abstract	
	20.	01/10/1991	WO 91/00293	WIPO				
	21.	01/23/1992	WO 92/00975	WIPO			Abstract	
	22.	04/16/1992	WO 92/05897	WIPO				
	23.	12/21/1995	WO 95/34326	WIPO				

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92) Sheet 2 of 4

Form PTO-1 INFORMATION OF SURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

2312005704

Application Number 09/752,533

Stephen M. COUTTS et al.

Filing Date December 29, 2000

Group Art Unit 1653

Mailing Date January 5, 2004

	24.	07/18/1996	WO 96/21469	WIPO	
	25.	06/17/1999	WO 99/29336	WIPO	
	26.	06/17/1999	WO 99/29338	WIPO	
	27.	07/15/1999	WO 99/34833	WIPO	
	28.	09/23/1999	WO 99/47494	WIPO	Abstract
-	29.	06/15/2000	WO 00/33887	WIPO	
	30.	06/15/2000	WO 00/34231	WIPO	
	31.	06/15/2000	WO 00/34296	WIPO	

		OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.)
Examiner Initials	Ref. No.	Title
	32.	Ashton, P. R. et al. (1996). "Amino Acid Derivatives of β-Cyclodextrin," J. Org. Chem. 61: 903-908.
	33.	Bordunov, A. V. et al. (1995). "Synthesis of New Pyridinoazacrown Ethers Containing Aromatic and Heteroaromatic Proton Ionizable Substituents," <i>J. Org. Chem.</i> 60: 6097-6102.
	34.	Brask, J. and Jensen, K.J. (2001). "Carboproteins: A 4-α-Helix Bundle Protein Model Assembled on a D-Galactopyranoside Template," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:697-700.
	35.	Choi, J.S. et al. (1999). "Poly(ethylene glycol)-block-poly(L-lysine) Dendrimer: Novel Linear Polymer/Dendrimer Block Copolymer Forming a Spherical Water-Soluble Polyionic Complex with DNA," <i>Bioconjug. Chem.</i> 10(1): 62-65.
	36.	Choi, J.S. et al. (2000). "Synthesis of a Barbell-like Triblock Copolymer, Poly(L-lysine) Dendrimer-block-Poly(ethylene glycol)-block-Poly(L-lysine) Dendrimer, and Its Self-Assembly with Plasmid DNA," J. Am. Chem. Soc. 122(3): 474-480.
	37.	Clark, A.J. et al. (2001). "A Nonisocyanate Route to Monodisperse Branched Polyurethanes," J. Org. Chem. 66:8687-8689.
	38.	Conrad, M.J. and Coutts, S. (1991). "Conjugates of Stable Polymer and Polynucleotide - Tolerogens for Human Systemic Lupus Erythematosus," Derwents Database record for European Patent No. EP 0 438 259, July 1991.
	39.	Contreras, M. A. et al. (1983). "Iodine Monochloride (ICI) Iodination Techniques" Chapter 22 In Methods in Enzymology Academic Press, Inc.: New York, New York 92:277-292.
	40.	Duncan, R. (1985). "Biological Effects of Soluble Synthetic Polymers as Drug Carriers," CRC Critical Reviews in Therapeutic Drug Carrier Systems. 1(4): 281-310.
	41.	Duncan, R. and Spreafico, F. (1994). "Polymer Conjugates: Pharmacokinetic Considerations for Design and Development," <i>Clin. Pharmacokinetic</i> 27(4):290-306.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

AMINDATE GANCELLED

JAN 0 5 2004

PTO/SB/08 (2-92) Sheet 3 of 4

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

2005704 Docket Number 2

Application Number 09/752,533

Applicant

Stephen M. COUTTS et al.

Filing Date December 29, 2000

Group Art Unit 1653

		Mailing Date January 5, 2004
42.		1995). "Synthesis and Characterization of Thermoplastic Graft or Main Chain and Uniform Urethane-Based Side Chains,"
43.		1995). "Thermoplastic Graft Copolymer Elastomers with ns," Macromol. Chem. Phys. 196(8):2669-2686.
44.	Fischer, M. and Vögtle, F. (1999). "Do Angew. Chem. Int. Ed. 38:884-905.	endrimers: From Design to Application - A Progress Report,"
45.		lective Halogenation at Primary Positions of thesis of Per-3,6-anhydro Cyclomaltooligosaccharides,"
46.		n: The Science and Practice of Pharmacy, 19th Edition. Mack Vol. I, pp. xv-xvi (Table of Contents Only.)
47.	Gitsov, I. et al. (1992). "Novel Polyethe Angew. Chem. Int. Ed. Engl. 31(9): 120	er Copolymers Consisting of Linear and Dendritic Blocks," 00-1202.
48.	Huang, S-Y. et al. (1998). "A Polyethy Copies of Cysteine-Containing Peptide	lene Glycol Copolymer for Carrying and Releasing Multiple s," <i>Bioconjug. Chem.</i> 9(5): 612-617.
49.	Iverson, G. M. et al. (1998). "A Chemi- β ₂ -Glycoprotein I Antibodies," <i>Lupus</i> 7	cally Defined, Toleragen-Based Approach for Targeting Anti-7(Supp. 2):S166-S169.
50.	Iverson, G. M. et al. (1998). "Anti-β2 on the First Domain of β2GPI," <i>Proc.</i> 1	Glycoprotein I (β2GPI) Autoantibodies Recognize an Epitope <i>Nat. Acad. Sci.</i> 95:15542-15546.
51.	Kono, K. et al. (1999). "Design of Den- Residues," <i>Bioconjug. Chem.</i> 10(6): 11	dritic Macromolecules Containing Folate or Methotrexate 15-1121.
52.		culating Lives of Single-Chain Fv Proteins Conjugated with Conjugation Chemistries and Compounds," <i>Bioconjug Chem</i>
53.	Lu, C. X. et al. (1988). "Nucleic Acid I Polymer Chem. 26(6):1659-1669.	Base Grafted Imino Polyurethane," J. Polymer Sci./ Part A:
54.	Mitchell, J. P.et al. (1999). "A Direct M Dendrimers," <i>Bioorganic & Medicinal</i>	Nethod for the Formation of Peptide and Carbohydrate Chemistry Letters 9:2785-2788.
55.	Pechar, M. et al. (2000). "Poly(ethylene Drug Doxorubicin," <i>Bioconjug. Chem.</i>	e glycol) Multiblock Copolymer as a Carrier of Anti-Cancer 11(2):131-139.
56.	· · · · · · · · · · · · · · · · · · ·	y Modified Recombinant Tumor Necrosis Factor-α Conjugated urface Grafted Polyethyleneglycol Chains," <i>Int. J. Pharm.</i> 184
57.	Talarico, T. L. et al. (2000). "Chemical Polyoxyethylene Conjugate," <i>Biochim.</i>	Characterization of Pyridoxalated Hemoglobin Biophys. Acta 1476: 53-65.
EXAMINER:		DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

MAIL DATE CANCELLED

JAN 0 5 2004 8

PTO/SB/08 (2-92) Sheet 4 of 4

Form PTO-1449 INFORMATION DESCRIPTION IN AN APPLICATION

(Use several sheets if necessary)

Application Number 09/752,533

Application Number 09/752,533

Application Number 09/752,533

· ----

Filing Date December 29, 2000 Group Art Unit 1653

Mailing Date January 5, 2004

58.	Taylor, R.T. and Puapaiboon, U. (1998). "Polyurethane Dendrimers via Curtius Reaction," <i>Tetrahedron Lett.</i> 39:8005-8008.
59.	Vercruysse, K.P. et al. (1997). "Synthesis and in Vitro Degradation of New Polyvalent Hydrazide Cross-Linked Hydrogels of Hyaluronic Acid," <i>Bioconjugate Chem.</i> 8:686-694.
60.	Veronese, F.M. and Morpurgo, M. (1999). "Bioconjugation in Pharmaceutical Chemistry," <i>Il Farmaco</i> 54: 497-516.
61.	Webb, M.S. et al. (1998). "Comparison of Different Hydrophobic Anchors Conjugated to Poly(ethylene glycol): Effects on the Pharmacokinetics of Liposomal Vincristine," <i>Biochim. Bioph Acta</i> 1372: 272-282.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.